Stability of Employment Status Among Patients with Highly Active Relapsing Multiple Sclerosis During the 2-year CLARIFY-MS Study

被引：0
|
作者：
Selmaj, K. [1 ]
Langdon, D. [2 ]
Brochet, B. [3 ]
Havrdova, E. K. [4 ]
Lechner-Scott, J. [5 ,6 ]
Montalban, X. [7 ]
Patti, F. [8 ,9 ]
Piehl, F. [10 ]
Solari, A. [11 ]
Alexandri, N. [12 ]
Nolting, A. [12 ]
Lehn, A. [12 ]
Smyk, A. [12 ]
机构：
[1] Ctr Neurol, Lodz, Poland
[2] Royal Holloway Univ London, Dept Psychol, Egham, Surrey, England
[3] Univ Bordeaux, INSERM U 1215, Bordeaux, France
[4] Charles Univ Prague, Med Fac 1, Prague, Czech Republic
[5] Univ Newcastle, Newcastle, NSW, Australia
[6] John Hunter Hosp, Div Neurol, Newcastle, NSW, Australia
[7] Univ Hosp Vall Hebron, Dept Neurol Neuroimmunol, Ctr Multiple Sclerosis Catalonia Cemcat, Barcelona, Spain
[8] Univ Catania, GF Ingrassia, Dept Med & Surg Sci & Adv Technol, Catania, Italy
[9] Univ Catania, Azienda Osped Univ Policlin G Rodolico San Marco, Catania, Italy
[10] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[11] Fdn IRCCS Ist Neurol Carlo Bes, Unit Neuroepidemiol, Milan, Italy
[12] Healthcare Business Merck KGaA, Darmstadt, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P089
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [41] Immunogenicity with peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis: 2-year data from the randomised phase 3, multicentre ADVANCE study in relapsing-remitting multiple sclerosis
    White, J. T.
    Kieseier, B. C.
    Newsome, S. D.
    Zhu, Y.
    Cui, Y.
    Seddighzadeh, A.
    Hung, S.
    Deykin, A.
    Subramanyam, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 346 - 346
  • [42] Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results
    Arroyo, E.
    Grau, C.
    Ramo, C.
    Parra, J.
    Sanchez-Solino, O.
    NEUROLOGIA, 2010, 25 (07): : 435 - 442
  • [43] Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
    Mark Gudesblatt
    Karl Wissemann
    Myassar Zarif
    Barbara Bumstead
    Lori Fafard
    Jeffrey Wilken
    Karen Blitz
    Marijean Buhse
    Sourav Santra
    Christophe Hotermans
    Lily Lee
    CNS Drugs, 2018, 32 : 1173 - 1181
  • [44] Voxel-based analysis of microstructural tissue damage in relapsing-remitting multiple sclerosis patients: a 2-year MRI longitudinal study
    Hannoun, S.
    Durand-Dubief, F.
    Ibarrola, D.
    Comte, J-C.
    Confavreux, C.
    Cotton, F.
    Sappey-Marinier, D.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S169 - S169
  • [45] Safety and tolerability of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis: 2-year data from the ADVANCE study
    Kieseier, B. C.
    Calabresi, P. A.
    Cui, Y.
    Zhu, Y.
    Hung, S.
    Deykin, A.
    Seddighzadeh, A.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 105 - 106
  • [46] Effects of Natalizumab (Tysabri®) on Gray Matter Pathology in Patients with Relapsing Multiple Sclerosis: A 2-Year Follow-Up Brain Atrophy Study
    Zivadinov, Robert
    Dwyer, Michael
    Hussein, Sara
    Carl, Ellen
    Kennedy, Cheryl
    Andrews, Michelle
    Hojnacki, David
    Heininen-Brown, Mari
    Willis, Laura
    Cherneva, Mariya
    Bergsland, Niels
    Weinstock-Guttman, Bianca
    NEUROLOGY, 2011, 76 (09) : A323 - A324
  • [47] Safety and clinical efficacy outcomes from the Long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
    Oh, J.
    Syed, S.
    Orogun, L.
    Xu, Z.
    Turner, T. J.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 342 - 343
  • [48] Adherence to Disease-Modifying Therapies in Patients with Relapsing Multiple Sclerosis: 2-Year Interim Results of the Global Adherence Project
    Arroyo, Estefania
    Grau, Cecilia
    Parra, Juan Carlos
    Solino, Olga Sanchez
    NEUROLOGY, 2010, 74 (09) : A546 - A546
  • [49] The feasibility and usability of a personal health record for patients with multiple sclerosis: a 2-year evaluation study
    van den Berg, Liselot N.
    Aardoom, Jiska J.
    Kiveron, Leone E.
    Botterweg, Robert D.
    van den Akker-van Marle, M. Elske
    Chavannes, Niels H.
    Hoitsma, Elske
    FRONTIERS IN HUMAN NEUROSCIENCE, 2024, 18
  • [50] Oral cladribine in relapsing-remitting multiple sclerosis: study design of the 2-year, Phase IIIb CLARITY (CLAdRIbine tablets Treating multiple sclerosis orallY) extension study
    Giovannoni, G.
    Cook, S.
    Greenberg, S.
    Chang, P.
    Comi, G.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    JOURNAL OF NEUROLOGY, 2008, 255 : 206 - 206
12345